Picture EBD Group Biotech Showcase 2023 San Francisco 650x100px
Employment/Membership › Details

Delfi Diagnostics–Meng J: management, 202207– Chief Commercial Officer before Myovant Sciences + Veracyte + Genentech


Period Period 2022-07-12
Organisations Organisation Delfi Diagnostics Inc.
  Organisation 2 Myovant Sciences Inc.
Products Product liquid biopsy
  Product 2 cancer test, early detection
Person Person Meng, Jessica (Delfi Diagnostics 202207– Chief Commercial Officer before Myovant Sciences + Veracyte + Genentech)

Delfi Diagnostics, Inc.. (7/12/22). "Press Release: Jessica Meng Joins Delfi Diagnostics as Chief Commercial Officer". Baltimore, MD.

Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has hired Jessica Meng as the company's first Chief Commercial Officer.

"Jessica is a strategic leader who has scaled commercial organizations in therapeutics and diagnostics and knows what it takes to commercialize successful oncology products," said Delfi Founder and CEO Victor Velculescu, MD, PhD. "We are excited to have her leadership as we prepare to introduce the first products on the Delfi platform."

Jessica is a proven commercial leader with a 20+ year track record in healthcare and extensive product launch leadership. She most recently led the Women's Health Division of Myovant Sciences as General Manager and Vice President of Sales & Marketing, where she played a key role in the formation of the co-promotion partnership with Pfizer. Prior to Myovant, Jessica was Vice President of Marketing for Veracyte, launching multiple genomic diagnostic products in oncology and pulmonology and helping to grow the commercial organization's headcount from 50 to 200. Jessica spent the bulk of her career in commercial leadership roles of increasing responsibilities at Genentech, most notably leading the marketing of Genentech's blockbuster oncology product, Avastin, to the height of its commercial success in gastrointestinal and gynecological cancers as well as glioblastoma.

"Delfi's platform has the potential to save lives all over the world," Meng said. "I am very thrilled to join this impressive team and to help bring Delfi's exciting new products to market."

About Delfi Diagnostics

Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi ("DNA Evaluation of Fragments for early Interception") is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.

Record changed: 2022-07-20


Picture [iito] Fighting Customers 650x100px

More documents for Delfi Diagnostics Inc.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x300px

» top